Landon Trost

2 weeks ago | urologytimes.com | Landon Trost |Benjamin P. Saylor

With the FDA’s recent class-wide labeling changes for testosterone products1, urologist Landon Trost, MD, told Urology Times® it will be easier for clinicians to counsel patients regarding testosterone therapy.

1 month ago | urologytimes.com | Landon Trost |Benjamin P. Saylor

When it comes to the FDA’s recent class-wide labeling changes for testosterone products,1 Landon Trost, MD, predicts that although the changes won’t significantly affect frequent prescribers of testosterone who are well versed in research on the treatment, it will nonetheless have an impact.